BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 31937122)

  • 1. Gender-related differences in patients treated with intravitreal anti-vascular endothelial growth factor medication for diabetic macular oedema.
    Schiefelbein J; Müller M; Kern C; Herold T; Liegl R; Fasler K; Jeliazkova D; Priglinger S; Kortuem KU
    Eur J Ophthalmol; 2020 Nov; 30(6):1410-1417. PubMed ID: 31937122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes.
    Lukic M; Williams G; Shalchi Z; Sim D; Patel PJ; Keane PA; Hykin PG; Sivaprasad S; Menon D; Bruynseels A; Hamilton RD; Rajendram R
    Eur J Ophthalmol; 2020 May; 30(3):557-562. PubMed ID: 30808179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes.
    Laugesen CS; Ostri C; Brynskov T; Lund-Andersen H; Larsen M; Vorum H; Sørensen TL
    Acta Ophthalmol; 2017 Feb; 95(1):28-32. PubMed ID: 27473397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes.
    Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
    Eur J Ophthalmol; 2021 May; 31(3):1201-1207. PubMed ID: 32429690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
    Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
    Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN
    Panos GD; Arruti N; Patra S
    Eur J Ophthalmol; 2021 Mar; 31(2):620-629. PubMed ID: 31906704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life anti-vascular endothelial growth factor treatment for age-related macular degeneration and diabetic macular edema in an Italian tertiary referral hospital.
    Battaglia Parodi M; Romano F; Arrigo A; Sacchi R; Scanzi G; Ferri C; Bandello F
    Eur J Ophthalmol; 2020 Nov; 30(6):1461-1466. PubMed ID: 31617403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab intravitreal injections in the treatment of diabetic macular oedema.
    Małgorzata W; Diana D; Agnieszka B; Zofia M
    Klin Oczna; 2013; 115(1):15-9. PubMed ID: 23882733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intravitreal dexamethasone implant on retinal and choroidal thickness in refractory diabetic macular oedema after multiple anti-VEGF injections.
    Kim M; Cho YJ; Lee CH; Lee SC
    Eye (Lond); 2016 May; 30(5):718-25. PubMed ID: 26939558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retinal Layers Changes in Patients with Diabetic Macular Edema Treated with Intravitreal Anti-VEGF Agents: Long-Term Outcomes of a Spectral-Domain OCT Study.
    Chatziralli I; Kazantzis D; Theodossiadis G; Theodossiadis P; Sergentanis TN
    Ophthalmic Res; 2021; 64(2):230-236. PubMed ID: 32564022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY ANALYSIS OF RETINAL DEGENERATIVE CHANGES IN DIABETIC MACULAR EDEMA AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Boiko EV; Maltsev DS
    Retina; 2018 Jul; 38(7):1324-1330. PubMed ID: 28492427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.
    Ozsaygili C; Duru N
    Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema.
    Wong Y; Steel DHW; Habib MS; Stubbing-Moore A; Bajwa D; Avery PJ;
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):733-742. PubMed ID: 27957600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OPTICAL COHERENCE TOMOGRAPHY BASELINE PREDICTORS FOR INITIAL BEST-CORRECTED VISUAL ACUITY RESPONSE TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN EYES WITH DIABETIC MACULAR EDEMA: The CHARTRES Study.
    Santos AR; Costa MÂ; Schwartz C; Alves D; Figueira J; Silva R; Cunha-Vaz JG
    Retina; 2018 Jun; 38(6):1110-1119. PubMed ID: 28613220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment.
    Santos AR; Alves D; Santos T; Figueira J; Silva R; Cunha-Vaz JG
    Retina; 2019 Jan; 39(1):52-60. PubMed ID: 29077605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
    Sheth S; Rush R; Natarajan S; Gillies M
    Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of ganglion cell layer cysts in diabetic macular oedema treated with anti-vascular endothelial growth factor.
    Ceklic L; Huf W; Ebneter A; Wolf S; Zinkernagel MS; Munk MR
    Acta Ophthalmol; 2019 Dec; 97(8):e1041-e1047. PubMed ID: 31099498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features.
    Hatz K; Ebneter A; Tuerksever C; Pruente C; Zinkernagel M
    Ophthalmologica; 2018; 239(4):205-214. PubMed ID: 29402873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.